Your browser is no longer supported. Please, upgrade your browser.
Settings
ACER Acer Therapeutics Inc. daily Stock Chart
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own16.80% Shs Outstand10.37M Perf Week6.59%
Market Cap30.75M Forward P/E- EPS next Y-1.63 Insider Trans13.51% Shs Float8.28M Perf Month9.13%
Income-21.10M PEG- EPS next Q-0.46 Inst Own39.40% Short Float5.13% Perf Quarter-24.86%
Sales- P/S- EPS this Y-17.20% Inst Trans-6.56% Short Ratio0.93 Perf Half Y45.50%
Book/sh1.08 P/B2.55 EPS next Y12.80% ROA-108.40% Target Price- Perf Year-16.67%
Cash/sh0.53 P/C5.21 EPS next 5Y- ROE-127.00% 52W Range1.08 - 7.25 Perf YTD-31.42%
Dividend- P/FCF- EPS past 5Y42.10% ROI- 52W High-57.93% Beta1.66
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low182.41% ATR0.21
Employees17 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)59.20 Volatility8.42% 8.10%
OptionableYes Debt/Eq0.00 EPS Q/Q49.10% Profit Margin- Rel Volume2.32 Prev Close2.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume458.23K Price3.05
Recom2.50 SMA2022.44% SMA50-5.50% SMA200-7.07% Volume627,469 Change10.91%
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Sep-28-20 03:30PM  
Aug-31-20 05:00PM  
Aug-25-20 09:00AM  
Aug-13-20 04:01PM  
Aug-05-20 09:00AM  
Jul-28-20 11:09AM  
Jul-27-20 07:29PM  
Jul-09-20 03:55PM  
03:43PM  
Jul-08-20 04:01PM  
Jun-24-20 01:53PM  
May-29-20 12:44PM  
May-21-20 08:30AM  
May-14-20 04:01PM  
May-11-20 04:05PM  
Apr-30-20 04:01PM  
Mar-18-20 04:05PM  
04:05PM  
Feb-26-20 03:00AM  
Feb-25-20 03:00AM  
Feb-24-20 04:05PM  
Jan-28-20 06:16PM  
Jan-05-20 07:00AM  
Dec-23-19 03:59PM  
Dec-17-19 07:56AM  
Dec-16-19 04:05PM  
Dec-05-19 12:50PM  
Nov-13-19 04:05PM  
Oct-28-19 04:01PM  
Oct-07-19 07:05AM  
Sep-11-19 08:00PM  
Aug-30-19 03:00PM  
02:30PM  
01:02PM  
10:04AM  
08:59AM  
Aug-29-19 10:00PM  
03:18PM  
12:27PM  
12:23PM  
Aug-28-19 09:34PM  
06:46PM  
01:00PM  
10:02AM  
Aug-27-19 10:00AM  
08:30AM  
06:35AM  
Aug-26-19 08:00PM  
07:33PM  
06:14PM  
Aug-25-19 10:28AM  
Aug-24-19 06:55AM  
Aug-23-19 08:00PM  
08:00PM  
06:06PM  
05:37PM  
03:00PM  
10:46AM  
Aug-22-19 08:45PM  
01:00PM  
06:30AM  
Aug-21-19 09:44PM  
10:45AM  
Aug-20-19 05:35PM  
03:08PM  
06:23AM  
Aug-19-19 07:07PM  
10:44AM  
09:15AM  
06:10AM  
Aug-16-19 09:35PM  
03:00PM  
02:14PM  
10:39AM  
Aug-15-19 11:25PM  
08:23PM  
04:37PM  
Aug-14-19 10:38AM  
06:50AM  
Aug-13-19 07:30PM  
04:05PM  
Aug-12-19 06:35PM  
10:37AM  
10:15AM  
09:19AM  
06:30AM  
Aug-10-19 12:00AM  
Aug-09-19 03:00PM  
10:08AM  
Aug-08-19 09:56PM  
06:35AM  
Aug-07-19 09:40PM  
04:38PM  
10:07AM  
Aug-06-19 06:09PM  
04:51PM  
Aug-05-19 06:05PM  
05:35PM  
12:05PM  
11:21AM  
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorJul 24Buy3.5045,000157,50063,905Jul 28 09:02 AM
Joseph DonaldChief Legal Officer and SecyJul 24Buy3.5014,28549,99814,285Jul 28 09:01 AM
DUNN JOHN MICHAELDirectorJul 24Buy3.5021,42874,99827,380Jul 28 09:01 AM
Schelling ChrisPresident & CEOJul 24Buy3.50142,857500,0001,892,857Jul 28 09:00 AM
ALVR AlloVir, Inc. daily Stock Chart
ALVR [NASD]
AlloVir, Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own36.40% Shs Outstand63.50M Perf Week-18.74%
Market Cap1.62B Forward P/E- EPS next Y-1.47 Insider Trans14.42% Shs Float23.45M Perf Month-4.68%
Income-30.70M PEG- EPS next Q-0.30 Inst Own- Short Float0.54% Perf Quarter-
Sales0.00M P/S- EPS this Y-192.30% Inst Trans- Short Ratio0.21 Perf Half Y-
Book/sh- P/B- EPS next Y-2.10% ROA- Target Price46.50 Perf Year-
Cash/sh1.82 P/C13.96 EPS next 5Y- ROE- 52W Range18.15 - 45.28 Perf YTD0.28%
Dividend- P/FCF- EPS past 5Y- ROI51.80% 52W High-42.62% Beta-
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin- 52W Low43.14% ATR3.72
Employees21 Current Ratio15.30 Sales Q/Q- Oper. Margin- RSI (14)49.19 Volatility16.29% 13.82%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.50 Prev Close25.46
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume591.98K Price25.98
Recom1.70 SMA20-1.06% SMA50-12.85% SMA200-12.85% Volume523,331 Change2.04%
Aug-24-20Initiated SVB Leerink Outperform $41
Aug-24-20Initiated Morgan Stanley Overweight $49
Aug-24-20Initiated JP Morgan Overweight $50
Sep-21-20 06:14AM  
Sep-17-20 09:49AM  
Sep-08-20 04:15PM  
Sep-02-20 07:30AM  
Aug-25-20 07:30AM  
Aug-03-20 04:30PM  
Jul-30-20 08:53AM  
07:32AM  
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jovan-Embiricos MoranaDirectorAug 03Buy17.002,900,00049,300,0002,800,000Aug 06 06:06 AM
VAN BEEK JEROEN BChief Commercial OfficerAug 03Buy17.003,00051,000524,640Aug 05 09:55 PM
Brainard DianaDirectorAug 03Buy17.006,300107,1006,300Aug 05 09:42 PM
Atillasoy ErcemSee RemarksAug 03Buy17.003,50059,50078,500Aug 05 09:39 PM
ALXO ALX Oncology Holdings Inc. daily Stock Chart
ALXO [NASD]
ALX Oncology Holdings Inc.
Index- P/E- EPS (ttm)-3.47 Insider Own2.60% Shs Outstand37.11M Perf Week7.11%
Market Cap1.48B Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float22.14M Perf Month-9.75%
Income-34.40M PEG- EPS next Q-0.36 Inst Own- Short Float1.52% Perf Quarter-
Sales3.70M P/S398.98 EPS this Y-33.70% Inst Trans- Short Ratio1.84 Perf Half Y-
Book/sh- P/B- EPS next Y-12.50% ROA- Target Price56.40 Perf Year-
Cash/sh2.64 P/C15.05 EPS next 5Y- ROE- 52W Range28.01 - 52.00 Perf YTD32.60%
Dividend- P/FCF- EPS past 5Y- ROI29.40% 52W High-24.06% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin9.10% 52W Low40.99% ATR3.75
Employees19 Current Ratio13.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)51.58 Volatility7.63% 9.89%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.36 Prev Close39.78
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume182.80K Price39.49
Recom1.80 SMA20-1.57% SMA50-0.14% SMA2000.34% Volume38,748 Change-0.73%
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
Sep-22-20 07:00AM  
Sep-17-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 04:05PM  
Jul-21-20 04:05PM  
Jul-17-20 04:17PM  
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
ANGO AngioDynamics, Inc. daily Stock Chart
ANGO [NASD]
AngioDynamics, Inc.
Index- P/E- EPS (ttm)-4.38 Insider Own2.60% Shs Outstand38.07M Perf Week7.56%
Market Cap394.79M Forward P/E86.75 EPS next Y0.12 Insider Trans4.45% Shs Float36.66M Perf Month15.10%
Income-166.80M PEG- EPS next Q-0.07 Inst Own98.00% Short Float2.32% Perf Quarter5.64%
Sales264.20M P/S1.49 EPS this Y-211.10% Inst Trans-0.79% Short Ratio3.14 Perf Half Y6.27%
Book/sh11.95 P/B0.89 EPS next Y220.00% ROA-24.30% Target Price14.00 Perf Year-40.82%
Cash/sh- P/C- EPS next 5Y15.00% ROE-29.10% 52W Range7.48 - 18.70 Perf YTD-33.35%
Dividend- P/FCF- EPS past 5Y4.38% ROI-33.50% 52W High-34.09% Beta0.57
Dividend %- Quick Ratio1.80 Sales past 5Y-5.80% Gross Margin56.90% 52W Low64.77% ATR0.41
Employees800 Current Ratio3.00 Sales Q/Q-18.10% Oper. Margin-63.30% RSI (14)84.39 Volatility6.20% 4.10%
OptionableYes Debt/Eq0.09 EPS Q/Q- Profit Margin-63.10% Rel Volume7.81 Prev Close10.67
ShortableYes LT Debt/Eq0.09 EarningsSep 29 BMO Payout- Avg Volume270.39K Price12.32
Recom3.00 SMA2029.16% SMA5033.37% SMA20011.24% Volume1,248,237 Change15.51%
Apr-08-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-01-19Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Apr-03-18Upgrade Raymond James Mkt Perform → Outperform
Jan-05-18Downgrade Craig Hallum Buy → Hold
Apr-07-17Reiterated Cantor Fitzgerald Overweight $20 → $21
Mar-30-17Downgrade KeyBanc Capital Mkts Overweight → Sector Weight
Feb-08-17Initiated Barclays Equal Weight $17
Nov-04-16Initiated Cantor Fitzgerald Buy
Apr-08-16Resumed Piper Jaffray Neutral
Jan-08-16Reiterated Canaccord Genuity Buy $17.50 → $14.50
Nov-10-15Downgrade Raymond James Outperform → Mkt Perform
Jul-24-15Initiated KeyBanc Capital Mkts Overweight
Jun-19-14Upgrade Canaccord Genuity Hold → Buy $16.25 → $20
Oct-09-12Reiterated Canaccord Genuity Hold $14 → $13.50
Jun-25-12Downgrade Canaccord Genuity Buy → Hold $16.50 → $14.50
Jul-15-11Upgrade Stifel Nicolaus Hold → Buy $16.50
Jul-15-11Upgrade Canaccord Genuity Hold → Buy $15 → $16.50
Jun-14-11Downgrade Wedbush Neutral → Underperform $14 → $12
Sep-08-10Reiterated Wedbush Neutral $17.50 → $14
Mar-04-10Initiated Wedbush Morgan Neutral $17.50
Sep-29-20 12:00PM  
08:44AM  
08:15AM  
07:00AM  
06:00AM  
Sep-28-20 10:07AM  
Sep-22-20 12:30PM  
08:37AM  
Sep-21-20 08:00AM  
Sep-17-20 04:01PM  
Aug-17-20 08:00AM  
Aug-15-20 11:30AM  
Aug-05-20 08:32AM  
Aug-04-20 08:09AM  
Aug-03-20 04:01PM  
09:32AM  
Jul-17-20 08:14AM  
Jul-16-20 02:30PM  
08:15AM  
07:25AM  
07:00AM  
Jul-09-20 12:30PM  
Jul-08-20 08:48AM  
Jul-04-20 03:00PM  
Jun-23-20 04:01PM  
Jun-17-20 09:16AM  
Jun-15-20 10:04AM  
Jun-08-20 04:01PM  
Jun-01-20 04:52PM  
May-07-20 04:01PM  
11:30AM  
Apr-13-20 02:32PM  
Apr-09-20 07:28AM  
Apr-07-20 09:46AM  
08:15AM  
07:00AM  
06:00AM  
Apr-01-20 06:30AM  
Mar-31-20 12:30PM  
Mar-25-20 12:00PM  
Mar-10-20 04:01PM  
Feb-27-20 04:01PM  
Feb-26-20 06:00AM  
Feb-09-20 09:34AM  
Feb-06-20 11:30AM  
08:00AM  
Jan-16-20 11:00AM  
Jan-09-20 06:27PM  
07:06AM  
Jan-08-20 09:02AM  
06:00AM  
Jan-07-20 08:15AM  
07:00AM  
Jan-06-20 08:00AM  
Jan-04-20 06:54AM  
Dec-31-19 12:30PM  
Dec-20-19 10:32AM  
06:00AM  
Dec-10-19 04:01PM  
Nov-26-19 07:37AM  
Nov-04-19 10:37AM  
05:43AM  
Nov-02-19 09:30AM  
Nov-01-19 01:04AM  
Oct-30-19 05:20PM  
Oct-23-19 07:54AM  
Oct-22-19 05:19PM  
04:01PM  
Oct-08-19 10:04AM  
Oct-07-19 06:00AM  
Oct-05-19 02:54AM  
Oct-04-19 07:03AM  
Oct-03-19 10:58AM  
07:30AM  
07:25AM  
07:08AM  
06:02AM  
06:00AM  
06:00AM  
Sep-26-19 10:30AM  
Sep-20-19 06:30AM  
Sep-09-19 08:00AM  
Sep-05-19 04:01PM  
Aug-15-19 11:05AM  
Aug-09-19 09:30AM  
Jul-31-19 04:01PM  
Jul-25-19 12:48PM  
Jul-23-19 04:01PM  
Jul-12-19 09:48AM  
Jul-11-19 11:07AM  
Jul-10-19 10:23PM  
04:46PM  
08:25AM  
07:29AM  
07:00AM  
06:00AM  
Jul-09-19 03:51PM  
Jul-06-19 02:45PM  
Jul-03-19 10:30AM  
Jun-27-19 11:33AM  
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trowbridge Stephen AEVP and CFOAug 11Buy9.381,0139,50260,273Aug 12 04:14 PM
Clemmer James CPresident and CEOJul 31Buy8.2640,000330,400343,319Aug 03 05:27 PM
Clemmer James CPresident and CEOOct 25Buy14.1915,000212,850260,418Oct 28 08:13 AM
ANNX Annexon, Inc. daily Stock Chart
ANNX [NASD]
Annexon, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own- Shs Outstand38.10M Perf Week11.49%
Market Cap935.35M Forward P/E- EPS next Y-1.65 Insider Trans- Shs Float22.69M Perf Month2.85%
Income-44.80M PEG- EPS next Q-0.35 Inst Own- Short Float1.34% Perf Quarter-
Sales- P/S- EPS this Y-107.10% Inst Trans- Short Ratio0.87 Perf Half Y-
Book/sh- P/B- EPS next Y17.10% ROA-64.30% Target Price33.00 Perf Year-
Cash/sh3.28 P/C7.49 EPS next 5Y38.60% ROE42.40% 52W Range15.33 - 29.71 Perf YTD38.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.26% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low75.86% ATR2.12
Employees30 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)65.94 Volatility9.08% 9.96%
OptionableNo Debt/Eq- EPS Q/Q-29.40% Profit Margin- Rel Volume1.22 Prev Close24.55
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume348.98K Price26.96
Recom1.70 SMA2012.35% SMA5016.14% SMA20016.14% Volume251,980 Change9.82%
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
Sep-08-20 04:01PM  
Jul-30-20 08:00AM  
Jul-28-20 04:05PM  
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
ASA ASA Gold and Precious Metals Limited daily Stock Chart
ASA [NYSE]
ASA Gold and Precious Metals Limited
Index- P/E2.95 EPS (ttm)7.14 Insider Own0.22% Shs Outstand19.29M Perf Week-7.19%
Market Cap406.05M Forward P/E- EPS next Y- Insider Trans8.66% Shs Float19.24M Perf Month-4.54%
Income- PEG- EPS next Q- Inst Own37.65% Short Float0.37% Perf Quarter24.34%
Sales1.31M P/S309.55 EPS this Y- Inst Trans- Short Ratio0.53 Perf Half Y100.10%
Book/sh18.88 P/B1.12 EPS next Y- ROA- Target Price- Perf Year69.76%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range8.16 - 25.45 Perf YTD54.44%
Dividend0.02 P/FCF- EPS past 5Y- ROI- 52W High-15.58% Beta-
Dividend %0.10% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low163.30% ATR0.90
Employees- Current Ratio- Sales Q/Q-41.60% Oper. Margin- RSI (14)41.95 Volatility4.39% 3.77%
OptionableYes Debt/Eq- EPS Q/Q442.90% Profit Margin- Rel Volume0.44 Prev Close21.05
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume134.95K Price21.49
Recom- SMA20-5.25% SMA50-5.77% SMA20032.70% Volume34,872 Change2.07%
Jul-31-20 03:54PM  
Jul-10-20 01:16PM  
Jun-10-20 03:19PM  
Mar-19-20 04:33PM  
Mar-13-20 04:21PM  
Dec-22-19 06:08PM  
Nov-01-19 04:00PM  
01:03PM  
Oct-29-19 09:00AM  
Sep-19-19 04:30PM  
Jul-22-19 04:32PM  
May-24-19 06:07AM  
May-09-19 10:54AM  
Apr-12-19 12:01PM  
Mar-26-19 02:33PM  
02:23PM  
02:13PM  
Jan-28-19 06:57PM  
Jan-26-19 05:00PM  
Dec-14-18 04:21PM  
Nov-02-18 05:17PM  
Sep-28-18 06:01PM  
Jul-26-18 05:50PM  
Mar-27-18 05:34PM  
Mar-15-18 02:21PM  
02:16PM  
Feb-15-18 09:00AM  
Feb-05-18 07:20AM  
Jan-29-18 03:47PM  
Jan-25-18 12:53PM  
Nov-02-17 03:30PM  
Sep-29-17 05:36PM  
Jul-26-17 04:17PM  
Mar-31-17 04:09PM  
Mar-16-17 04:37PM  
04:35PM  
Jan-27-17 04:05PM  
Dec-13-16 09:20PM  
Oct-31-16 06:23PM  
Sep-30-16 04:15PM  
Jul-29-16 09:57AM  
Jul-25-16 05:38PM  
Apr-01-16 05:51PM  
Mar-16-16 05:42PM  
05:36PM  
Mar-15-16 02:12PM  
Mar-05-16 12:01AM  
Jan-28-16 07:26PM  
06:56PM  
Jan-11-16 07:30AM  
Dec-08-15 06:17AM  
Nov-27-15 10:02AM  
Nov-23-15 02:28PM  
Nov-12-15 07:00AM  
Nov-06-15 01:52PM  
Sep-24-15 04:14PM  
Jul-25-15 02:52AM  
Jul-16-15 02:49PM  
Mar-31-15 04:46PM  
04:25PM  
Mar-18-15 03:00AM  
Mar-13-15 05:10PM  
05:06PM  
Mar-12-15 04:01PM  
03:04PM  
Feb-09-15 09:55AM  
Jan-28-15 07:26PM  
07:21PM  
Nov-04-14 11:17AM  
Oct-20-14 10:55AM  
Oct-01-14 05:54PM  
Sep-25-14 09:08PM  
Jul-14-14 05:58PM  
Mar-31-14 07:07AM  
Mar-28-14 06:10PM  
Mar-17-14 06:05PM  
Mar-13-14 04:23PM  
Feb-07-14 05:42PM  
Jan-28-14 05:31PM  
Jan-10-14 07:00AM  
Dec-30-13 09:16AM  
Nov-04-13 06:03PM  
Sep-20-13 08:00AM  
Aug-02-13 11:23AM  
07:44AM  
Aug-01-13 10:45AM  
Jul-30-13 07:39AM  
01:31AM  
Jul-26-13 11:10AM  
10:43AM  
Jul-22-13 01:10PM  
05:16AM  
Jun-14-13 06:55AM  
Jun-05-13 03:46PM  
May-31-13 09:38AM  
May-30-13 07:36AM  
May-28-13 11:15AM  
May-20-13 01:30PM  
08:18AM  
May-16-13 06:00PM  
ASA Gold and Precious Metals Limited is a publicly owned investment manager. The firm invests in the public equity markets across the globe. It primarily invests in stocks of companies engaged in the exploration, mining or processing of gold, silver, platinum, diamonds, or other precious minerals. It also invests in exchange traded funds. The firm employs fundamental analysis with a bottom-up approach to create its portfolios. The firm obtains external research to complement its in-house research. ASA Gold and Precious Metals Limited was founded in 1958 and is based in San Mateo, California with an additional office in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Merk AlexanderCOOSep 25Buy20.852,08043,37532,270Sep 25 04:50 PM
Merk AlexanderCOOJul 24Buy22.141,27028,12413,355Jul 24 03:44 PM
Merk AlexanderCOOMar 16Buy8.9010,00089,02812,085Mar 16 04:28 PM
Hoene Mary JoanDirectorMar 09Buy12.841001,2844,700Mar 09 02:01 PM
Maletis PeterPresidentJan 17Buy13.625006,810500Jan 21 03:35 PM
Hoene Mary JoanDirectorJan 16Buy13.582002,7164,600Jan 16 03:59 PM
Artabane Anthony J.DirectorJan 15Buy13.472,50033,67533,800Jan 15 02:51 PM
ASB Associated Banc-Corp daily Stock Chart
ASB [NYSE]
Associated Banc-Corp
Index- P/E5.99 EPS (ttm)2.13 Insider Own1.30% Shs Outstand152.39M Perf Week0.79%
Market Cap1.92B Forward P/E13.25 EPS next Y0.96 Insider Trans1.71% Shs Float150.39M Perf Month-8.20%
Income332.10M PEG1.00 EPS next Q0.19 Inst Own75.70% Short Float1.67% Perf Quarter-4.99%
Sales1.05B P/S1.84 EPS this Y6.00% Inst Trans-0.93% Short Ratio1.98 Perf Half Y-1.85%
Book/sh24.09 P/B0.53 EPS next Y-38.74% ROA1.00% Target Price15.56 Perf Year-37.20%
Cash/sh14.81 P/C0.86 EPS next 5Y6.00% ROE9.10% 52W Range10.23 - 22.60 Perf YTD-42.11%
Dividend0.72 P/FCF3.11 EPS past 5Y10.50% ROI17.60% 52W High-45.00% Beta1.24
Dividend %5.64% Quick Ratio- Sales past 5Y9.70% Gross Margin- 52W Low21.51% ATR0.50
Employees4669 Current Ratio- Sales Q/Q-26.60% Oper. Margin76.00% RSI (14)41.75 Volatility3.97% 3.59%
OptionableYes Debt/Eq0.42 EPS Q/Q91.00% Profit Margin31.70% Rel Volume0.46 Prev Close12.76
ShortableYes LT Debt/Eq0.42 EarningsJul 23 AMC Payout33.10% Avg Volume1.27M Price12.43
Recom3.10 SMA20-5.42% SMA50-7.07% SMA200-19.28% Volume344,256 Change-2.59%
Jul-09-20Downgrade Jefferies Buy → Hold
Mar-30-20Upgrade Wells Fargo Underweight → Equal Weight $19 → $15
Feb-20-20Upgrade Raymond James Underperform → Mkt Perform
Jan-06-20Downgrade Wells Fargo Equal Weight → Underweight $20
Dec-03-19Downgrade Robert W. Baird Outperform → Neutral
Jan-10-19Downgrade BofA/Merrill Neutral → Underperform
Jan-08-19Upgrade Jefferies Hold → Buy
Jan-07-19Downgrade Raymond James Mkt Perform → Underperform
Oct-19-18Downgrade Sandler O'Neill Buy → Hold
Apr-20-18Upgrade Sandler O'Neill Hold → Buy
Jan-02-18Reiterated Barclays Equal Weight $27 → $29
Mar-29-17Upgrade SunTrust Hold → Buy
Feb-02-17Initiated JMP Securities Mkt Perform
Jan-12-17Initiated Piper Jaffray Neutral
Dec-21-16Initiated SunTrust Hold $26
Dec-15-16Upgrade BofA/Merrill Underperform → Neutral
Nov-28-16Downgrade Jefferies Buy → Hold
Apr-01-16Downgrade Macquarie Neutral → Underperform
Jan-22-16Reiterated RBC Capital Mkts Sector Perform $20 → $19
Jan-13-16Upgrade Deutsche Bank Hold → Buy $20
Sep-23-20 03:38PM  
Sep-15-20 04:20PM  
Sep-10-20 08:15AM  
07:30AM  
Sep-07-20 06:25AM  
Sep-02-20 07:53AM  
Sep-01-20 06:28PM  
Aug-26-20 06:13AM  
Aug-22-20 11:30AM  
Aug-18-20 04:48PM  
04:15PM  
Aug-11-20 12:34PM  
Aug-06-20 04:15PM  
Aug-03-20 01:10PM  
Jul-31-20 12:09PM  
Jul-30-20 04:28PM  
Jul-27-20 06:00PM  
Jul-24-20 08:47AM  
Jul-23-20 09:31PM  
04:47PM  
03:51PM  
Jul-13-20 03:09PM  
Jul-01-20 10:34AM  
Jun-30-20 04:05PM  
08:50AM  
Jun-28-20 07:16PM  
Jun-25-20 04:15PM  
Jun-24-20 01:34PM  
Jun-19-20 10:25AM  
Jun-16-20 05:36PM  
Jun-11-20 10:37AM  
Jun-09-20 10:17AM  
Jun-04-20 05:19PM  
May-26-20 08:12AM  
May-23-20 11:30AM  
May-17-20 08:25AM  
May-15-20 04:15PM  
May-14-20 12:31PM  
May-06-20 11:23AM  
May-04-20 04:01PM  
Apr-30-20 09:03AM  
Apr-28-20 04:15PM  
Apr-24-20 11:50AM  
Apr-23-20 03:00PM  
Apr-21-20 06:23AM  
Apr-16-20 12:31PM  
Apr-15-20 08:34AM  
Apr-01-20 09:20AM  
Mar-27-20 03:56PM  
11:38AM  
Mar-26-20 05:11PM  
Mar-23-20 05:00PM  
Mar-21-20 08:00PM  
06:22PM  
Mar-19-20 09:15AM  
Mar-16-20 04:15PM  
Mar-15-20 04:30PM  
Mar-04-20 09:15AM  
Feb-25-20 04:42PM  
Feb-23-20 07:12AM  
Feb-22-20 11:30AM  
Feb-19-20 03:49PM  
Feb-18-20 09:15AM  
Feb-14-20 04:15PM  
Feb-10-20 04:15PM  
Jan-31-20 08:36AM  
Jan-30-20 08:44AM  
Jan-27-20 07:46PM  
Jan-26-20 06:52AM  
Jan-24-20 08:23AM  
Jan-23-20 06:15PM  
Jan-22-20 10:33AM  
07:36AM  
07:28AM  
Jan-21-20 08:56AM  
Jan-20-20 09:36AM  
08:15AM  
Jan-17-20 07:26AM  
Jan-16-20 12:30PM  
08:25AM  
06:33AM  
Jan-15-20 09:50AM  
08:18AM  
07:43AM  
Jan-14-20 09:45AM  
09:42AM  
Jan-13-20 09:26AM  
Jan-08-20 12:10PM  
Jan-06-20 03:25PM  
Jan-03-20 07:33AM  
Dec-30-19 09:10AM  
Dec-27-19 04:15PM  
Dec-11-19 04:15PM  
Dec-10-19 04:15PM  
Dec-09-19 02:31PM  
Dec-08-19 07:28PM  
Dec-02-19 09:00AM  
Nov-22-19 05:17AM  
Nov-20-19 09:02AM  
Nov-05-19 09:20AM  
Associated Banc-Corp, a bank holding company, provides various banking and nonbanking products to individuals and businesses in Wisconsin, Illinois, and Minnesota. Its Corporate and Commercial Specialty segment offers deposit and cash management solutions, such as commercial checking and interest-bearing deposit products, cash vault and night depository services, liquidity solutions, payables and receivables solutions, and information services; and lending solutions, including commercial loans and lines of credit, commercial real estate financing, construction loans, letters of credit, leasing, asset based lending, and loan syndications. This segment also provides specialized financial services comprising interest rate risk management, foreign exchange solutions, and commodity hedging. The company's Community, Consumer, and Business segment offers checking, credit, debit and pre-paid cards, online banking and bill pay, and money transfer services; residential mortgages, home equity loans and lines of credit, personal and installment loans, real estate financing, business loans, and business lines of credit; savings, money market deposit accounts, IRA accounts, certificates of deposit, and fixed and variable annuities, as well as full-service, discount, and online investment brokerage; investment advisory services; trust and investment management accounts; and insurance and other related products and services. This segment also engages in the administration of pension, profit-sharing and other employee benefit plans, fiduciary and corporate agency services, and institutional asset management services. Its Risk Management and Shared Services segment provides corporate risk management, credit administration, finance, treasury, operations, and technology services. As of December 31, 2019, the company operated 248 banking branches serving over 120 communities. Associated Banc-Corp was founded in 1861 and is headquartered in Green Bay, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Del Moral-Niles ChristopherChief Financial OfficerAug 03Buy12.982,00025,96042,342Aug 05 12:01 PM
Haddad Michael JDirectorJun 09Buy25.002,00050,0002,000Jun 11 01:12 PM
KLAPPA GALE EDirectorJun 09Buy25.002,00050,0002,000Jun 11 01:09 PM
Lau Timothy JExecutive Vice PresidentJun 09Buy25.001,00025,0001,000Jun 11 01:01 PM
GERKEN R JAYDirectorJun 09Buy25.002,00050,0002,000Jun 11 12:54 PM
Crowley Michael T JrDirectorJun 09Buy25.004,000100,0004,000Jun 11 12:49 PM
BERGSTROM JOHN FDirectorJun 09Buy25.0020,000500,00020,000Jun 11 12:46 PM
Crowley Michael T JrDirectorMar 12Buy12.212,00024,420721,508Mar 13 04:12 PM
HUTCHINSON WILLIAM RDirectorMar 09Buy13.175,00065,85099,097Mar 09 05:21 PM
Crowley Michael T JrDirectorMar 09Buy13.454,00053,800719,508Mar 09 07:12 PM
HUTCHINSON WILLIAM RDirectorMar 09Buy13.345,00066,68694,097Mar 09 02:03 PM
Crowley Michael T JrDirectorMar 06Buy15.755,00078,750715,508Mar 06 12:50 PM
Crowley Michael T JrDirectorMar 03Buy17.055,00085,25096,643Mar 03 03:09 PM
Crowley Michael T JrDirectorFeb 27Buy17.305,00086,500710,508Feb 27 03:11 PM
Crowley Michael T JrDirectorFeb 25Buy18.695,00093,445705,508Feb 25 03:15 PM
WILLIAMS JOHN BDirectorFeb 11Sale20.532,36048,44143,130Feb 12 03:51 PM
Lau Timothy JExecutive Vice PresidentFeb 05Sale20.734,00082,91446,910Feb 06 12:29 PM
Hankerd John P.Executive Vice PresidentJan 28Sale20.576,000123,40215,566Jan 29 01:10 PM
Hankerd John P.Executive Vice PresidentNov 25Sale21.753,00065,25921,566Nov 26 01:32 PM
Stadler Tammy C.Principal Accounting OfficerNov 21Option Exercise13.165,80076,32841,991Nov 22 10:49 AM
Stadler Tammy C.Principal Accounting OfficerNov 21Sale21.505,800124,70036,191Nov 22 10:49 AM
BOHN WILLIAM MExecutive Vice PresidentNov 13Option Exercise17.6715,481273,54973,721Nov 14 05:26 PM
BOHN WILLIAM MExecutive Vice PresidentNov 13Sale21.5315,481333,29458,240Nov 14 05:26 PM
Del Moral-Niles ChristopherChief Financial OfficerNov 11Sale21.734,00086,90038,007Nov 12 01:29 PM
Stein David LExecutive Vice PresidentNov 08Option Exercise12.9720,000259,40069,835Nov 12 12:27 PM
Del Moral-Niles ChristopherChief Financial OfficerNov 08Option Exercise17.2425,000431,00064,275Nov 12 01:29 PM
Stein David LExecutive Vice PresidentNov 08Sale21.7920,000435,80049,835Nov 12 12:27 PM
Utz John A.Executive Vice PresidentOct 29Sale20.482,00040,96756,745Oct 31 01:32 PM
AXGT Axovant Gene Therapies Ltd. daily Stock Chart
AXGT [NASD]
Axovant Gene Therapies Ltd.
Index- P/E- EPS (ttm)-1.96 Insider Own0.20% Shs Outstand43.29M Perf Week2.18%
Market Cap178.07M Forward P/E- EPS next Y-1.37 Insider Trans166.08% Shs Float23.26M Perf Month57.58%
Income-53.20M PEG- EPS next Q-0.33 Inst Own30.00% Short Float1.14% Perf Quarter62.50%
Sales- P/S- EPS this Y63.50% Inst Trans2.78% Short Ratio0.39 Perf Half Y99.15%
Book/sh1.35 P/B3.47 EPS next Y-14.20% ROA-75.10% Target Price- Perf Year-29.20%
Cash/sh1.46 P/C3.21 EPS next 5Y- ROE-149.50% 52W Range1.41 - 6.93 Perf YTD-8.59%
Dividend- P/FCF- EPS past 5Y-10.10% ROI- 52W High-31.60% Beta1.14
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low236.17% ATR0.38
Employees38 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)73.37 Volatility13.71% 9.74%
OptionableYes Debt/Eq0.00 EPS Q/Q83.90% Profit Margin- Rel Volume2.24 Prev Close4.68
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume683.31K Price4.74
Recom1.60 SMA2029.63% SMA5043.14% SMA20036.09% Volume904,145 Change1.28%
Apr-17-20Initiated Cantor Fitzgerald Overweight $11
Oct-28-19Reiterated Chardan Capital Markets Buy $10 → $15
Aug-12-19Upgrade Robert W. Baird Neutral → Outperform $16 → $13
Jun-21-19Initiated SVB Leerink Outperform $18
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Upgrade Chardan Capital Markets Neutral → Buy $4
Sep-22-20 08:56AM  
Sep-15-20 08:00AM  
Sep-10-20 08:33AM  
Sep-08-20 07:30AM  
Aug-11-20 07:00AM  
Jul-31-20 07:45AM  
06:30AM  
Jul-13-20 07:02PM  
Jul-05-20 08:46PM  
Jun-24-20 12:00AM  
Jun-10-20 06:00AM  
Jun-08-20 07:30AM  
Jun-02-20 12:00PM  
May-28-20 08:00AM  
May-18-20 11:43AM  
May-12-20 01:40PM  
May-07-20 08:00AM  
May-05-20 10:55AM  
Apr-24-20 07:30AM  
Apr-15-20 08:00AM  
Apr-08-20 12:00PM  
08:00AM  
Mar-31-20 08:00AM  
Mar-10-20 06:46AM  
Feb-24-20 04:01PM  
Feb-19-20 10:11PM  
04:02PM  
Feb-10-20 06:00AM  
Jan-13-20 06:30AM  
Jan-06-20 12:00PM  
Dec-23-19 02:19PM  
Dec-20-19 08:12AM  
Dec-19-19 05:41PM  
Dec-03-19 07:00AM  
Nov-19-19 09:40AM  
Nov-18-19 07:30AM  
Nov-14-19 08:34AM  
Nov-13-19 09:00AM  
Nov-08-19 08:00AM  
Nov-05-19 08:00AM  
Oct-23-19 07:00AM  
Oct-20-19 08:08AM  
Oct-10-19 08:00AM  
Oct-09-19 09:00AM  
Sep-27-19 05:45PM  
Sep-25-19 04:05PM  
Sep-19-19 05:50PM  
Sep-13-19 05:45PM  
Sep-12-19 09:15AM  
Aug-12-19 05:48PM  
Aug-09-19 07:00AM  
Aug-08-19 10:45AM  
10:15AM  
09:26AM  
Aug-02-19 10:48AM  
10:43AM  
10:04AM  
Jul-29-19 05:50PM  
11:40AM  
Jul-16-19 08:17AM  
Jul-12-19 05:45PM  
Jul-10-19 07:04AM  
Jul-08-19 09:55AM  
Jul-03-19 02:19PM  
Jul-01-19 07:00AM  
Jun-28-19 08:35PM  
Jun-26-19 08:58AM  
Jun-24-19 07:01AM  
Jun-21-19 03:35PM  
10:34AM  
Jun-20-19 09:42AM  
07:00AM  
Jun-14-19 09:00AM  
Jun-11-19 06:18PM  
04:05PM  
Jun-06-19 07:40AM  
Jun-04-19 04:16PM  
May-31-19 07:00AM  
May-30-19 08:44AM  
May-29-19 10:40AM  
May-28-19 09:02AM  
May-27-19 05:00AM  
May-21-19 05:34AM  
May-20-19 03:06PM  
07:00AM  
May-17-19 05:33PM  
May-16-19 04:05PM  
May-14-19 09:05AM  
May-07-19 04:15PM  
Apr-30-19 07:00AM  
Apr-25-19 02:35PM  
Apr-16-19 07:00AM  
Apr-10-19 09:00AM  
Apr-05-19 07:48AM  
Apr-04-19 04:10PM  
Mar-29-19 07:00AM  
Mar-18-19 07:45AM  
Mar-14-19 11:02AM  
07:00AM  
Mar-13-19 04:21PM  
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pande AtulDirectorJul 08Buy2.7310,00027,29023,370Jul 10 06:12 PM
Cheruvu PavanPrincipal Executive OfficerJul 08Buy2.7437,500102,63857,836Jul 10 06:11 PM
Pande AtulDirectorMar 16Buy1.7810,00017,84413,370Mar 18 08:20 PM
Roivant Sciences Ltd.10% OwnerFeb 24Buy3.755,333,33319,999,99918,577,380Feb 27 07:49 PM
AZZ AZZ Inc. daily Stock Chart
AZZ [NYSE]
AZZ Inc.
Index- P/E27.75 EPS (ttm)1.24 Insider Own1.70% Shs Outstand26.16M Perf Week2.60%
Market Cap896.36M Forward P/E12.28 EPS next Y2.80 Insider Trans3.62% Shs Float25.74M Perf Month-0.89%
Income32.50M PEG2.78 EPS next Q0.43 Inst Own92.90% Short Float1.81% Perf Quarter0.70%
Sales986.00M P/S0.91 EPS this Y-4.40% Inst Trans1.15% Short Ratio2.98 Perf Half Y25.06%
Book/sh24.30 P/B1.41 EPS next Y44.07% ROA2.90% Target Price44.25 Perf Year-19.86%
Cash/sh1.01 P/C33.95 EPS next 5Y10.00% ROE5.10% 52W Range19.31 - 49.46 Perf YTD-25.29%
Dividend0.68 P/FCF9.69 EPS past 5Y-6.30% ROI7.50% 52W High-31.66% Beta1.39
Dividend %1.98% Quick Ratio1.00 Sales past 5Y5.30% Gross Margin21.60% 52W Low75.04% ATR0.99
Employees4343 Current Ratio1.40 Sales Q/Q-26.20% Oper. Margin6.40% RSI (14)49.83 Volatility3.06% 2.74%
OptionableYes Debt/Eq0.34 EPS Q/Q-74.00% Profit Margin3.30% Rel Volume0.62 Prev Close34.33
ShortableYes LT Debt/Eq0.15 EarningsJul 09 BMO Payout54.90% Avg Volume156.59K Price33.80
Recom2.30 SMA20-1.53% SMA500.37% SMA200-2.89% Volume56,953 Change-1.54%
Oct-29-18Upgrade Sidoti Neutral → Buy
May-18-18Reiterated Stifel Hold $48 → $47
Sep-27-17Reiterated Stifel Hold $56 → $52
Jul-07-17Reiterated Stifel Hold $58 → $56
Jan-10-17Upgrade Stifel Sell → Hold $57 → $60
Dec-08-16Downgrade Stifel Hold → Sell $63 → $57
Mar-28-16Resumed Stifel Hold
Jan-11-16Downgrade BB&T Capital Mkts Buy → Hold
Oct-12-15Downgrade Sidoti Buy → Neutral
Jun-12-15Downgrade DA Davidson Buy → Neutral $52 → $55
Jan-25-13Upgrade BB&T Capital Mkts Hold → Buy $49
Jul-07-11Initiated BB&T Capital Mkts Hold
Apr-08-11Reiterated Hudson Securities Buy $47 → $53
Jan-21-11Upgrade Hudson Securities Hold → Buy $43 → $47
Dec-07-10Initiated Stifel Nicolaus Hold
Oct-01-10Downgrade Hudson Securities Buy → Hold $48 → $45
Jun-29-09Upgrade Next Generation Neutral → Buy
May-30-08Initiated DA Davidson Buy
Jan-19-07Initiated Next Generation Neutral $54
Sep-23-20 03:37PM  
Sep-14-20 04:05PM  
06:53AM  
Sep-09-20 04:30PM  
Aug-24-20 05:12AM  
Aug-22-20 10:12AM  
Aug-11-20 12:27PM  
Jul-30-20 09:48AM  
Jul-21-20 06:30AM  
Jul-19-20 05:32PM  
Jul-09-20 09:00AM  
07:10AM  
06:30AM  
04:03AM  
Jul-08-20 04:05PM  
Jul-02-20 04:05PM  
Jun-24-20 04:05PM  
10:21AM  
Jun-16-20 11:31AM  
May-28-20 06:55AM  
May-12-20 11:50AM  
May-04-20 04:05PM  
Apr-30-20 12:55PM  
Apr-29-20 07:14AM  
06:30AM  
Apr-22-20 04:11PM  
12:31PM  
Apr-15-20 04:06PM  
Apr-14-20 06:43AM  
Mar-22-20 08:15AM  
Mar-16-20 05:21PM  
Mar-03-20 07:49AM  
07:45AM  
Mar-02-20 06:30AM  
Feb-11-20 07:10AM  
06:30AM  
Jan-27-20 06:30AM  
05:02AM  
Jan-21-20 09:08PM  
06:30AM  
Jan-17-20 06:30AM  
Jan-14-20 10:30PM  
Jan-12-20 07:33AM  
Jan-10-20 08:54AM  
Jan-09-20 11:00AM  
06:46AM  
06:30AM  
Jan-03-20 12:30PM  
11:55AM  
11:00AM  
10:27AM  
03:00AM  
Jan-02-20 10:50PM  
06:35PM  
06:05PM  
10:45AM  
12:15AM  
Jan-01-20 12:14AM  
Dec-31-19 07:20PM  
05:53PM  
02:35PM  
12:30PM  
10:45AM  
Dec-30-19 10:50PM  
06:53PM  
06:29PM  
03:00PM  
02:30PM  
11:30AM  
Dec-29-19 10:55PM  
11:00AM  
10:45AM  
Dec-28-19 03:40PM  
10:02AM  
Dec-27-19 10:50PM  
06:25PM  
06:00PM  
04:05PM  
03:35PM  
Dec-26-19 10:20PM  
08:35PM  
07:00PM  
06:32PM  
05:10PM  
10:45AM  
Dec-25-19 10:50PM  
Dec-24-19 10:50PM  
08:00PM  
04:15PM  
02:30PM  
02:30PM  
11:00AM  
Dec-23-19 10:50PM  
Dec-22-19 11:55AM  
Dec-20-19 10:50PM  
01:30PM  
10:00AM  
09:45AM  
Dec-19-19 08:20PM  
05:15PM  
AZZ Inc. provides galvanizing and metal coating solutions, welding solutions, specialty electrical equipment, and highly engineered services to the power generation, transmission, distribution, refining, and industrial markets. The company operates through two segments, Energy and Metal Coatings. The Energy segment provides specialized products and services designed to support industrial, electrical, and nuclear applications. It offers custom switchgear, electrical enclosures, medium and high voltage bus ducts, explosion proof and hazardous duty lighting, nuclear safety-related equipment, and tubular products to multi-national companies and small independent companies. This segment sells its products through internal sales force, manufacturers' representatives, distributors, and agents. The Metal Coatings segment offers hot dip galvanizing, powder coating, anodizing, plating, and other metal coating applications to the steel fabrication and other industries. It serves fabricators or manufacturers that provide services to the electrical and telecommunications, bridge and highway, petrochemical, and general industrial markets, as well as original equipment manufacturers. As of February 29, 2020, the company operated forty galvanizing plants, one galvabar plant, and seven surface technologies plants located in various locations in the United States and Canada. AZZ Inc. was founded in 1956 and is headquartered in Fort Worth, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lavelle KenPresident & GM - ElectricalJul 15Buy30.835,500169,56510,290Jul 15 06:23 PM
FERGUSON THOMAS EPresident and CEOJul 14Buy28.9410,000289,376109,794Jul 15 04:53 PM
Stovall Bryan LeePresident-Galv SolutionsMay 22Option Exercise0.00701016,811May 26 05:00 PM
Hill Gary L.President & GM-IndustrialMay 22Option Exercise0.0097308,851May 26 04:59 PM
Lavelle KenPresident & GM - ElectricalMay 22Option Exercise0.0097304,298May 26 04:59 PM
Mackey Tara DChief Legal OfficerMay 22Option Exercise0.001,168010,758May 26 05:00 PM
Doucet MichaelSVP-Surface TechnologiesMay 22Option Exercise0.0038802,352May 26 04:58 PM
FERGUSON THOMAS EPresident and CEOMay 22Option Exercise0.005,8440100,488May 26 04:59 PM
Bacius Chris M.VP, Corporate DevelopmentMay 22Option Exercise0.00876010,900May 26 04:58 PM
EMERY MATTHEW VARLEYChief Information & HR OfficerMay 22Option Exercise0.0087608,684May 26 04:58 PM
Mackey Tara DChief Legal OfficerMay 18Option Exercise0.001,22109,887May 19 05:21 PM
Stovall Bryan LeePresident-Galv SolutionsMay 18Option Exercise0.00407016,208May 19 05:21 PM
FERGUSON THOMAS EPresident and CEOMay 18Option Exercise0.004,887095,833May 19 05:20 PM
Hill Gary L.President & GM-IndustrialMay 18Option Exercise0.001,01808,186May 19 05:20 PM
Lavelle KenPresident & GM - ElectricalMay 18Option Exercise0.001,01803,572May 19 05:20 PM
Bacius Chris M.VP, Corporate DevelopmentMay 18Option Exercise0.00916010,246May 19 05:18 PM
Doucet MichaelSVP-Surface TechnologiesMay 18Option Exercise0.0040702,059May 19 05:19 PM
EMERY MATTHEW VARLEYChief Information & HR OfficerMay 18Option Exercise0.0091608,030May 19 05:19 PM
Lavelle KenPresident & GM - ElectricalApr 27Option Exercise0.0030002,642Apr 29 04:44 PM
Mackey Tara DChief Legal OfficerApr 27Option Exercise0.0043108,793Apr 29 04:44 PM
Stovall Bryan LeePresident-Galv SolutionsApr 27Option Exercise0.00259015,877Apr 29 04:44 PM
Fehlman Paul WesleySVP & CFOApr 27Option Exercise0.001,058016,595Apr 29 04:42 PM
FERGUSON THOMAS EPresident and CEOApr 27Option Exercise0.002,593091,576Apr 29 04:43 PM
Hill Gary L.President & GM-IndustrialApr 27Option Exercise0.0043107,321Apr 29 04:43 PM
Bacius Chris M.VP, Corporate DevelopmentApr 27Option Exercise0.0043109,457Apr 29 04:41 PM
Doucet MichaelSVP-Surface TechnologiesApr 27Option Exercise0.0018001,693Apr 29 04:42 PM
EMERY MATTHEW VARLEYChief Information & HR OfficerApr 27Option Exercise0.0043107,241Apr 29 04:42 PM
Stovall Bryan LeeSVP - Metal CoatingsOct 24Option Exercise0.00503015,740Oct 25 04:44 PM
BCBP BCB Bancorp, Inc. daily Stock Chart
BCBP [NASD]
BCB Bancorp, Inc.
Index- P/E9.70 EPS (ttm)0.85 Insider Own6.10% Shs Outstand17.18M Perf Week0.61%
Market Cap139.16M Forward P/E13.98 EPS next Y0.59 Insider Trans2.83% Shs Float14.80M Perf Month1.61%
Income14.20M PEG0.97 EPS next Q0.11 Inst Own37.10% Short Float1.46% Perf Quarter-10.16%
Sales119.00M P/S1.17 EPS this Y18.80% Inst Trans-4.82% Short Ratio6.09 Perf Half Y-20.35%
Book/sh14.03 P/B0.59 EPS next Y10.94% ROA0.50% Target Price9.17 Perf Year-36.57%
Cash/sh25.19 P/C0.33 EPS next 5Y10.00% ROE6.00% 52W Range7.73 - 14.50 Perf YTD-40.39%
Dividend0.56 P/FCF28.40 EPS past 5Y8.20% ROI25.80% 52W High-45.31% Beta0.55
Dividend %6.81% Quick Ratio- Sales past 5Y15.50% Gross Margin- 52W Low2.59% ATR0.21
Employees365 Current Ratio- Sales Q/Q-11.40% Oper. Margin64.90% RSI (14)45.63 Volatility3.42% 2.35%
OptionableYes Debt/Eq0.15 EPS Q/Q-53.20% Profit Margin12.00% Rel Volume0.79 Prev Close8.22
ShortableYes LT Debt/Eq0.15 Earnings- Payout65.90% Avg Volume35.36K Price7.93
Recom3.00 SMA20-1.94% SMA50-4.44% SMA200-23.27% Volume16,468 Change-3.53%
Jan-31-20Downgrade DA Davidson Buy → Neutral
Jan-14-19Initiated Sandler O'Neill Hold
Feb-27-18Downgrade Keefe Bruyette Outperform → Mkt Perform
Sep-14-17Initiated Keefe Bruyette Outperform $14
Sep-29-20 09:53AM  
Aug-02-20 08:10AM  
Jul-27-20 06:45PM  
05:11PM  
04:24PM  
Jul-14-20 09:27AM  
Jul-10-20 12:30PM  
Jun-22-20 10:35AM  
Jun-12-20 01:34PM  
May-07-20 10:19AM  
Apr-27-20 06:45PM  
04:23PM  
Apr-22-20 08:48AM  
Apr-14-20 06:51AM  
Apr-09-20 12:30PM  
Apr-02-20 12:10PM  
Mar-09-20 08:26AM  
Mar-02-20 09:00AM  
Feb-01-20 06:58AM  
Jan-27-20 04:15PM  
Jan-22-20 05:32AM  
Jan-21-20 04:00PM  
Jan-06-20 09:00AM  
Dec-30-19 10:36AM  
Dec-22-19 07:43PM  
Dec-02-19 10:25AM  
Nov-05-19 06:33AM  
05:26AM  
Oct-24-19 11:14AM  
Oct-18-19 04:15PM  
Oct-14-19 07:05AM  
Oct-09-19 04:15PM  
09:10AM  
Sep-23-19 04:00PM  
Sep-20-19 10:55AM  
09:40AM  
09:10AM  
Sep-19-19 07:34AM  
Sep-18-19 06:42AM  
Sep-11-19 09:08AM  
Sep-10-19 07:30AM  
Sep-04-19 09:30AM  
09:10AM  
Aug-26-19 07:39AM  
Aug-19-19 09:30AM  
09:10AM  
Aug-03-19 09:17AM  
Jul-24-19 06:27AM  
Jul-19-19 05:45PM  
04:15PM  
Jul-11-19 04:15PM  
May-29-19 08:58AM  
Apr-18-19 04:21PM  
04:15PM  
Apr-15-19 10:30AM  
Apr-12-19 09:00AM  
Mar-18-19 11:48AM  
Feb-26-19 04:30PM  
Feb-01-19 09:30AM  
09:10AM  
Jan-31-19 05:45PM  
04:46PM  
04:15PM  
Jan-21-19 10:23AM  
Jan-14-19 04:15PM  
Nov-28-18 09:53AM  
Nov-14-18 05:19AM  
Nov-12-18 07:53AM  
Nov-02-18 01:15PM  
Nov-01-18 07:48AM  
Oct-30-18 08:11AM  
Oct-19-18 05:15PM  
04:10PM  
04:00PM  
Oct-11-18 10:30AM  
Aug-29-18 12:16PM  
Jul-30-18 07:10PM  
06:02PM  
04:08PM  
01:39PM  
Jul-13-18 04:15PM  
Jun-20-18 01:57PM  
Jun-12-18 06:27AM  
Jun-04-18 06:14AM  
Jun-01-18 03:14PM  
May-22-18 09:07PM  
May-09-18 10:06AM  
May-07-18 08:13AM  
Apr-30-18 05:26AM  
Apr-24-18 07:14PM  
Apr-23-18 09:07AM  
09:00AM  
Apr-17-18 05:00PM  
Apr-16-18 05:46PM  
Apr-09-18 12:09PM  
Mar-30-18 03:15PM  
12:39PM  
Mar-16-18 09:53AM  
Mar-15-18 08:24AM  
Mar-13-18 04:06PM  
BCB Bancorp, Inc. operates as a bank holding company for BCB Community Bank, a state-chartered commercial bank that provides banking products and services to businesses and individuals in the United States. The company offers deposit products, including interest and non-interest bearing demand, NOW, savings and club, money market, term certificate, interest bearing checking, and individual retirement accounts. It also provides loans, such as commercial and multi-family real estate loans, commercial and residential property construction loans, commercial business loans, small business administration loans, home equity loans and home equity lines of credit, and consumer loans; and residential loans secured by one-to-four family dwellings, condominiums, and cooperative units. In addition, the company offers retail and commercial banking services comprising wire transfers, money orders, safe deposit boxes, night depository services, debit cards, online and mobile banking services, gift cards, fraud detection services, and automated teller services. As of January 31, 2019, it operated 28 branch offices in Bayonne, Carteret, Colonia, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lodi, Lyndhurst, Maplewood, Monroe Township, Parsippany, Plainsboro, Rutherford, South Orange, Union, and Woodbridge, New Jersey; and 3 branches in Hicksville and Staten Island, New York. The company was founded in 2000 and is headquartered in Bayonne, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rizzo James G.DirectorSep 18Buy8.281,0008,28037,618Sep 21 11:13 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerSep 18Buy8.992,50022,475206,916Sep 21 11:14 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerSep 17Buy8.191,0008,19057,974Sep 21 11:14 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerSep 17Buy8.191,0008,190204,416Sep 21 11:14 AM
Robbins Spencer B.DirectorAug 27Buy8.125004,06059,317Aug 28 10:07 AM
BALLANCE ROBERTDirectorAug 25Buy8.175004,085113,099Aug 27 10:28 AM
Rizzo James G.DirectorAug 18Buy8.281,0008,28060,654Aug 18 02:31 PM
Rizzo James G.DirectorAug 10Buy8.761,0008,76059,654Aug 11 11:41 AM
HOGAN MARK DDirectorAug 06Buy8.162,00016,32063,421Aug 06 03:50 PM
HOGAN MARK DChairman of the BoardJul 31Buy7.961,0007,960503,025Aug 03 12:41 PM
HOGAN MARK DChairman of the BoardJul 31Buy8.135,00040,63061,421Jul 31 11:30 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerJul 30Buy8.251,0008,25056,974Jul 31 09:50 AM
Rizzo James G.DirectorJul 30Buy8.251,0008,25036,618Jul 30 02:37 PM
PELLEGRINI AUGUST JRDirectorJul 30Buy8.172,00016,340115,556Jul 31 10:03 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerJun 19Buy8.891,0008,89055,974Jun 23 11:12 AM
HOGAN MARK DDirectorJun 19Buy8.862,00017,71056,421Jun 22 10:21 AM
Rizzo James G.DirectorJun 19Buy8.851,0008,85035,618Jun 19 03:32 PM
HOGAN MARK DDirectorJun 15Buy9.141,0009,14054,421Jun 16 11:47 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerJun 12Buy9.201,10010,12054,974Jun 15 10:54 AM
HOGAN MARK DDirectorJun 11Buy8.841,0008,84053,421Jun 12 01:35 PM
Robbins Spencer B.DirectorMay 28Buy10.034004,01258,817May 28 04:16 PM
Robbins Spencer B.DirectorMay 12Buy9.212001,842300May 12 05:19 PM
Robbins Spencer B.DirectorMay 01Buy9.952001,99058,417May 01 05:53 PM
Emerson KennethSVP/Chief Strategy&Risk OffcrMar 18Buy9.903,00029,7133,000Mar 20 01:58 PM
Rizzo James G.DirectorMar 16Buy8.705004,35058,654Mar 17 12:47 PM
Robbins Spencer B.DirectorMar 13Buy9.665004,83058,217Mar 13 03:32 PM
Rizzo James G.DirectorMar 12Buy9.461,50014,19558,154Mar 12 06:01 PM
COUGHLIN THOMAS MICHAELChief Executive OfficerMar 12Buy9.631,0009,63053,874Mar 12 05:59 PM
BIELAN JUDITH QDirectorMar 11Buy10.491,25013,11310,734Mar 13 03:27 PM
BIELAN JUDITH QDirectorMar 11Buy10.494504,72178,407Mar 13 03:27 PM
LYGA JOSEPHDirectorMar 10Buy10.771,71118,422137,367Mar 10 04:38 PM
PELLEGRINI AUGUST JRDirectorMar 10Buy10.631,00010,630113,556Mar 11 04:40 PM
Rizzo James G.DirectorMar 09Buy10.405005,20056,654Mar 10 11:28 AM
COUGHLIN THOMAS MICHAELChief Executive OfficerMar 06Buy11.531,00011,530203,416Mar 09 01:46 PM
BALLANCE ROBERTDirectorMar 06Buy11.321,00011,320112,599Mar 09 01:39 PM
Rizzo James G.DirectorMar 06Buy11.281,50016,92555,654Mar 06 05:33 PM
Rizzo James G.DirectorFeb 27Buy11.8490010,65654,654Feb 27 04:56 PM
LYGA JOSEPHDirectorFeb 26Buy12.541001,2542,616Feb 26 04:58 PM
LYGA JOSEPHDirectorFeb 26Buy12.542002,508135,656Feb 26 04:58 PM
Rizzo James G.DirectorFeb 26Buy12.282503,0703,100Feb 26 06:18 PM
Rizzo James G.DirectorFeb 25Buy12.502503,12553,754Feb 26 06:18 PM
Rizzo James G.DirectorFeb 24Buy12.631,00012,63453,504Feb 26 06:18 PM
BROGAN JOSEPH JDirectorFeb 21Buy12.783,15040,257350,528Feb 26 04:57 PM
Keating ThomasChief Financial OfficerFeb 07Buy13.045006,52012,500Feb 11 12:04 PM
BCLI Brainstorm Cell Therapeutics Inc. daily Stock Chart
BCLI [NASD]
Brainstorm Cell Therapeutics Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own1.20% Shs Outstand29.27M Perf Week10.00%
Market Cap477.38M Forward P/E- EPS next Y-0.70 Insider Trans-5.27% Shs Float25.08M Perf Month31.82%
Income-28.80M PEG- EPS next Q-0.26 Inst Own19.90% Short Float15.29% Perf Quarter43.82%
Sales- P/S- EPS this Y-52.20% Inst Trans80.05% Short Ratio6.91 Perf Half Y253.66%
Book/sh0.34 P/B46.91 EPS next Y39.10% ROA-223.40% Target Price22.33 Perf Year311.08%
Cash/sh0.54 P/C29.47 EPS next 5Y- ROE- 52W Range3.58 - 17.20 Perf YTD272.66%
Dividend- P/FCF- EPS past 5Y-9.40% ROI- 52W High-7.56% Beta0.86
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin- 52W Low344.13% ATR0.85
Employees32 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)66.04 Volatility6.51% 6.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-11.90% Profit Margin- Rel Volume0.64 Prev Close15.95
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume554.68K Price15.90
Recom2.00 SMA2014.57% SMA5015.77% SMA20090.75% Volume210,425 Change-0.31%
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Sep-29-20 06:00AM  
Sep-16-20 07:30AM  
Sep-03-20 09:00AM  
Sep-02-20 08:30AM  
Aug-25-20 07:39AM  
Aug-19-20 08:13AM  
Aug-10-20 09:03AM  
07:30AM  
Aug-07-20 05:50AM  
Aug-05-20 07:00AM  
Jul-27-20 07:58AM  
Jul-23-20 04:36PM  
07:00AM  
Jul-09-20 09:10AM  
Jul-08-20 05:31AM  
Jul-02-20 06:49AM  
Jul-01-20 08:50AM  
Jun-25-20 08:26AM  
Jun-24-20 09:06AM  
07:00AM  
Jun-23-20 05:45AM  
Jun-15-20 09:00AM  
Jun-11-20 07:28AM  
Jun-10-20 05:40AM  
Jun-09-20 06:00AM  
Jun-04-20 07:09PM  
Jun-03-20 06:00AM  
Jun-02-20 06:00AM  
May-27-20 07:25AM  
May-18-20 06:06AM  
May-08-20 05:35AM  
May-07-20 06:30AM  
01:00AM  
May-04-20 03:30AM  
Apr-29-20 06:00AM  
Apr-08-20 06:40AM  
Apr-03-20 06:59AM  
Apr-01-20 09:00AM  
Mar-31-20 04:00AM  
Mar-16-20 03:00AM  
Mar-06-20 09:25AM  
Feb-27-20 01:00AM  
Feb-20-20 05:10AM  
Feb-18-20 07:00AM  
06:00AM  
Feb-17-20 01:00AM  
Feb-11-20 06:00AM  
Feb-10-20 01:00AM  
Feb-04-20 04:45AM  
Jan-29-20 04:00AM  
Jan-21-20 09:53AM  
Jan-17-20 06:00AM  
Jan-07-20 01:00AM  
Jan-03-20 10:21AM  
Dec-19-19 05:00AM  
Dec-18-19 05:00AM  
Dec-11-19 05:00AM  
Nov-26-19 08:05AM  
Nov-25-19 06:00AM  
Nov-21-19 06:15AM  
Nov-20-19 07:00AM  
Nov-18-19 06:32AM  
Nov-14-19 08:07AM  
07:00AM  
06:00AM  
Nov-13-19 05:00AM  
Nov-12-19 01:00AM  
Nov-05-19 06:15AM  
Oct-28-19 07:45AM  
Oct-25-19 01:00AM  
Oct-24-19 08:45AM  
Oct-23-19 01:00AM  
Oct-11-19 01:00AM  
Oct-07-19 08:04AM  
Oct-02-19 06:45AM  
Sep-27-19 04:00AM  
Sep-19-19 09:19AM  
Sep-09-19 01:00AM  
Sep-06-19 01:50AM  
Aug-16-19 10:30AM  
Aug-13-19 07:30AM  
06:00AM  
Aug-05-19 01:00AM  
Jul-10-19 07:08AM  
Jul-02-19 08:15AM  
May-31-19 01:00AM  
May-30-19 01:00AM  
May-28-19 01:00AM  
May-21-19 10:15AM  
May-13-19 01:00AM  
May-10-19 05:00PM  
Apr-30-19 04:00AM  
Apr-04-19 10:30AM  
Mar-28-19 04:30AM  
Mar-26-19 06:30AM  
Mar-18-19 10:26PM  
Mar-15-19 10:50AM  
Mar-14-19 01:00AM  
Mar-13-19 11:57AM  
Mar-12-19 07:47AM  
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Setboun DavidEVP and COOJul 16Buy12.955,00064,74055,000Jul 16 05:10 PM
ACC International Holdings LtdMember of 10% owner groupJul 16Sale13.477,823105,35167,053Jul 16 05:05 PM
Abbhi SankeshDirectorJul 15Buy12.9946,779607,6592,164,530Jul 16 05:15 PM
ACC International Holdings LtdMember of 10% owner groupJul 15Sale13.1218,430241,71574,876Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 13Sale13.5240,000540,95293,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 10Sale13.352,00026,700133,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 09Sale13.133,50045,939135,306Jul 16 05:05 PM
Shah PreetamEVP, CFO and TreasurerDec 24Buy3.9611,60045,92936,600Dec 27 07:01 AM
Kern Ralph Dr.COO and Chief Medical OfficerDec 24Buy3.883,00011,640115,655Dec 27 07:01 AM
Araya ArturoChief Commercial OfficerDec 24Buy3.903,00011,7008,608Dec 27 07:00 AM
BKCC BlackRock Capital Investment Corporation daily Stock Chart
BKCC [NASD]
BlackRock Capital Investment Corporation
Index- P/E- EPS (ttm)-1.48 Insider Own1.35% Shs Outstand70.17M Perf Week-4.49%
Market Cap178.94M Forward P/E5.10 EPS next Y0.50 Insider Trans6.41% Shs Float- Perf Month-7.94%
Income- PEG- EPS next Q0.12 Inst Own37.70% Short Float- Perf Quarter-2.67%
Sales75.35M P/S2.37 EPS this Y-11.90% Inst Trans- Short Ratio1.49 Perf Half Y11.22%
Book/sh4.84 P/B0.53 EPS next Y-3.80% ROA- Target Price3.40 Perf Year-48.13%
Cash/sh- P/C- EPS next 5Y3.00% ROE- 52W Range1.43 - 5.05 Perf YTD-47.14%
Dividend0.40 P/FCF- EPS past 5Y-10.74% ROI- 52W High-50.51% Beta-
Dividend %15.69% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low75.05% ATR0.13
Employees- Current Ratio- Sales Q/Q-11.00% Oper. Margin- RSI (14)45.45 Volatility3.98% 4.94%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.58 Prev Close2.55
ShortableYes LT Debt/Eq- EarningsJul 29 AMC Payout- Avg Volume367.53K Price2.50
Recom3.00 SMA20-4.32% SMA50-6.32% SMA200-23.44% Volume126,033 Change-1.96%
Nov-04-19Upgrade Wells Fargo Market Perform → Outperform
Jan-16-19Downgrade JP Morgan Neutral → Underweight
Nov-05-18Downgrade JP Morgan Overweight → Neutral
Feb-06-18Upgrade JP Morgan Neutral → Overweight
Apr-28-16Downgrade DA Davidson Buy → Neutral $10 → $9
Feb-19-16Downgrade Keefe Bruyette Outperform → Mkt Perform
Sep-30-15Initiated DA Davidson Buy $10
Jul-01-15Initiated Cantor Fitzgerald Buy
May-21-15Downgrade BofA/Merrill Neutral → Underperform
Nov-04-11Upgrade Ladenburg Thalmann Neutral → Buy $8 → $9.50
Apr-27-11Upgrade UBS Neutral → Buy $11 → $11
Dec-02-10Initiated UBS Neutral $11
Apr-28-10Downgrade Stifel Nicolaus Buy → Hold
Jan-25-10Upgrade Stifel Nicolaus Hold → Buy $11
Apr-23-09Initiated Fox Pitt In Line
Mar-05-09Upgrade Stifel Nicolaus Sell → Hold
Dec-10-08Initiated Stifel Nicolaus Sell
Aug-29-08Downgrade Wachovia Outperform → Mkt Perform
Sep-17-07Initiated Wachovia Outperform
Aug-07-07Initiated Citigroup Hold
Jul-30-20 09:01PM  
Jul-29-20 04:25PM  
04:02PM  
Jul-01-20 04:00PM  
Jun-25-20 09:30AM  
May-22-20 07:16PM  
May-15-20 09:24AM  
May-08-20 11:17AM  
09:30AM  
May-06-20 04:02PM  
11:50AM  
Apr-16-20 04:01PM  
04:01PM  
Apr-15-20 04:01PM  
Mar-27-20 06:14AM  
06:02AM  
Mar-04-20 04:02PM  
Jan-30-20 04:00PM  
Jan-24-20 02:18PM  
Oct-30-19 04:02PM  
Oct-16-19 04:24PM  
Oct-01-19 04:01PM  
Sep-28-19 07:49AM  
Aug-22-19 10:08AM  
Aug-06-19 12:52AM  
Jul-31-19 06:55PM  
04:02PM  
Jul-24-19 10:32AM  
Jul-10-19 01:55PM  
Jul-01-19 04:00PM  
May-02-19 02:46PM  
May-01-19 07:05PM  
05:53PM  
04:02PM  
Apr-24-19 10:33AM  
Apr-23-19 07:00AM  
Apr-02-19 04:01PM  
Mar-15-19 08:36AM  
Mar-12-19 09:22AM  
Mar-07-19 12:45PM  
Mar-06-19 04:02PM  
10:54AM  
Feb-15-19 07:30AM  
Feb-01-19 08:51AM  
06:45AM  
Jan-31-19 04:00PM  
Jan-10-19 11:03AM  
Nov-07-18 07:40AM  
Nov-05-18 07:10PM  
Oct-31-18 06:10PM  
05:04PM  
04:02PM  
Oct-10-18 07:55AM  
Oct-01-18 04:01PM  
Aug-17-18 01:40PM  
Aug-02-18 08:00AM  
Aug-01-18 07:00PM  
05:52PM  
04:02PM  
Jul-02-18 04:00PM  
Jun-29-18 11:24AM  
06:45AM  
Jun-28-18 07:50AM  
May-23-18 08:30AM  
May-08-18 09:56PM  
May-02-18 05:40PM  
04:02PM  
May-01-18 03:37PM  
Apr-30-18 05:15PM  
Apr-03-18 04:01PM  
Mar-30-18 07:40AM  
Mar-09-18 04:06AM  
Mar-07-18 04:43PM  
04:02PM  
Feb-01-18 04:00PM  
Jan-29-18 08:25AM  
Jan-15-18 09:12AM  
Nov-21-17 09:29AM  
Nov-13-17 03:53PM  
Nov-09-17 07:50AM  
Nov-08-17 04:47PM  
04:02PM  
Oct-24-17 04:02PM  
Oct-02-17 04:00PM  
Sep-26-17 09:00AM  
Sep-05-17 07:37AM  
Sep-04-17 10:37AM  
09:07AM  
07:38AM  
Sep-01-17 05:06PM  
03:22PM  
Aug-28-17 08:34AM  
Aug-12-17 03:21AM  
Aug-09-17 07:37AM  
Aug-08-17 09:09AM  
Aug-07-17 04:55PM  
Aug-04-17 02:34AM  
Aug-02-17 04:31PM  
Jul-03-17 04:00PM  
Jun-26-17 10:00AM  
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pungello MichaelInterim CFO/Interim TreasurerAug 11Buy2.948,00023,48043,872Aug 11 05:44 PM
Keenan JamesInterim CEOAug 07Buy2.8425,00071,000287,479Aug 11 04:01 PM
Keenan JamesInterim CEOAug 03Buy2.6724,07664,285262,479Aug 05 01:29 PM
Keenan JamesInterim CEOMar 10Buy4.2750,000213,565231,768Mar 10 04:34 PM
Harris Jerrold BDirectorMar 10Buy4.188,50035,53031,757Mar 12 03:30 PM
Lies Mark SDirectorMar 09Buy4.1935,000146,608265,000Mar 10 04:34 PM
Keenan JamesInterim CEOMar 09Buy4.0460,489244,357181,768Mar 10 04:34 PM
Pungello MichaelInterim CFO/Interim TreasurerMar 09Buy4.1710,00041,69434,583Mar 09 04:00 PM
Pungello MichaelInterim CFO/Interim TreasurerDec 03Buy4.995,00024,94924,583Dec 03 04:04 PM
Keenan JamesInterim CEODec 02Buy4.9430,279149,515121,279Dec 03 04:24 PM
BSET Bassett Furniture Industries, Incorporated daily Stock Chart
BSET [NASD]
Bassett Furniture Industries, Incorporated
Index- P/E- EPS (ttm)-2.23 Insider Own4.10% Shs Outstand9.96M Perf Week2.22%
Market Cap133.67M Forward P/E20.21 EPS next Y0.66 Insider Trans22.15% Shs Float9.32M Perf Month4.87%
Income-22.10M PEG- EPS next Q-0.07 Inst Own57.70% Short Float1.38% Perf Quarter84.00%
Sales399.00M P/S0.34 EPS this Y-121.00% Inst Trans-12.30% Short Ratio1.42 Perf Half Y127.65%
Book/sh15.28 P/B0.87 EPS next Y137.70% ROA-6.50% Target Price14.00 Perf Year-11.48%
Cash/sh2.90 P/C4.59 EPS next 5Y16.00% ROE-12.80% 52W Range4.25 - 18.24 Perf YTD-20.02%
Dividend0.32 P/FCF- EPS past 5Y-17.20% ROI-0.40% 52W High-24.95% Beta1.63
Dividend %2.40% Quick Ratio0.70 Sales past 5Y5.80% Gross Margin59.30% 52W Low222.12% ATR0.98
Employees2555 Current Ratio1.30 Sales Q/Q-41.00% Oper. Margin-7.90% RSI (14)63.86 Volatility9.31% 7.17%
OptionableYes Debt/Eq0.01 EPS Q/Q- Profit Margin-5.50% Rel Volume0.41 Prev Close13.34
ShortableYes LT Debt/Eq0.01 EarningsJul 09 BMO Payout- Avg Volume90.24K Price13.69
Recom- SMA206.05% SMA5024.64% SMA20041.07% Volume22,079 Change2.62%
Jun-30-17Reiterated Stifel Hold $28 → $36
Apr-06-16Initiated Stifel Hold
Jan-27-16Downgrade Sidoti Buy → Neutral
Jan-21-16Upgrade Sidoti Neutral → Buy
Jan-27-15Reiterated Wm Smith Not Rated $20 → $25
Sep-12-14Initiated Wm Smith Not Rated $20
Sep-22-20 07:39AM  
Aug-08-20 08:26AM  
Aug-06-20 11:26AM  
Jul-17-20 09:00AM  
Jul-16-20 04:01PM  
Jul-13-20 06:00AM  
Jul-09-20 11:05AM  
10:02AM  
09:00AM  
Jul-08-20 09:17PM  
Jun-30-20 12:30PM  
May-24-20 09:46AM  
May-11-20 09:55AM  
Apr-24-20 11:52AM  
Apr-22-20 09:00AM  
Apr-18-20 08:31AM  
Apr-04-20 08:29AM  
Apr-02-20 10:25AM  
09:00AM  
Mar-26-20 12:30PM  
Mar-17-20 01:47PM  
Mar-12-20 06:19PM  
Feb-28-20 05:53AM  
Jan-28-20 07:23AM  
05:30AM  
Jan-23-20 10:35AM  
09:00AM  
Jan-16-20 04:54PM  
Jan-09-20 12:30PM  
Jan-05-20 07:36AM  
Dec-17-19 07:35PM  
08:50AM  
Dec-10-19 06:46AM  
Nov-08-19 05:40AM  
Nov-02-19 02:27PM  
Oct-19-19 09:20AM  
Oct-17-19 09:00AM  
Oct-10-19 09:00AM  
Oct-03-19 10:15AM  
09:00AM  
Sep-29-19 09:20AM  
Sep-19-19 10:30AM  
Sep-09-19 09:04AM  
Aug-20-19 07:13AM  
Aug-07-19 07:38AM  
Jul-31-19 07:32AM  
Jul-18-19 09:00AM  
Jul-08-19 03:24PM  
Jul-02-19 11:05AM  
09:00AM  
Jun-20-19 10:30AM  
Jun-14-19 11:52AM  
May-13-19 07:07AM  
Apr-24-19 10:36AM